XFOR Stock — X4 Pharmaceuticals Inc.: Cash, EV, Pipeline

What they do

We are a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with partners.

Source: 10-K FY2025 via SEC EDGAR

Share price

$3.18

Market cap

$324.7M

Cash

$187.7M

Enterprise value

$212.0M

Balance sheet

Cash	$187.7M
Debt	$75.0M
Net cash	$112.7M
Enterprise value	$212.0M
Basic shares	102.1M shares
Fully diluted shares	113.8M shares
Fully diluted market cap	$362.0M
Cash per share	$1.84
Quarterly burn	$20.8M
Cash runway	10.0 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

99.1M

Pre-funded warrants

0.0M

Options

12.1M

RSUs

0.1M

Warrants

2.5M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

—

FDSO

113.8M

Cap table as of 2026-06-30.

Price history

Loading XFOR daily closes…

Loading price history…

Next catalyst

Mavorixafor · Oct 13 - Nov 24 in 11 mo · Phase 3 · Neutropenia

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Oct 13 - Nov 24 in 11 mo	Mavorixafor	Phase 3	Neutropenia	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Mavorixafor

Phase 3 · Active Modality: small molecule (CXCR4 antagonist)

Aliases XOLREMDI, X4P-001

Target CXCR4

Partnerships Genzyme (Sanofi) license: regulatory/sales milestones (a $5M regulatory milestone paid in H1 2026 upon EMA MAA validation). Norgine Pharma UK license and supply agreement (Q1 2025): €28.5M upfront plus regulatory milestones (€5.5M received to date); R&D services for WHIM studies and the global Phase 3 CN trial.

Indications

WHIM syndrome (warts, hypogammaglobulinemia, infections, myelokathexis) (Approved)
Chronic neutropenia (congenital, acquired primary autoimmune, idiopathic) (Phase 3)

Status note Lead and sole commercial asset, on which the company depends almost entirely for revenue. FDA accelerated approval for oral once-daily use in WHIM syndrome patients ≥12 years to increase circulating mature neutrophils and lymphocytes; EU marketing authorization also granted. Global pivotal 52-week Phase 3 4WARD trial in chronic neutropenia ongoing (mavorixafor ± G-CSF); FDA Fast Track designation for CN.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Mavorixafor
Lead indication	Neutropenia
Lead phase	Phase 3
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06056297	Phase 3	Recruiting	Sponsor	X4 Pharmaceuticals	—	Neutropenia	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for X4 Pharmaceuticals on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Perceptive Advisors	7,933,491	+1,195,843	0.58%	2026-08-14
Braidwell LP	2,922,754	-350,200	0.50%	2026-08-14
BVF Partners	2,233,742	no change	0.27%	2026-08-14
Stonepine Capital	224,989	-110,320	0.80%	2026-08-17

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

XFOR — X4 Pharmaceuticals Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

XFOR — X4 Pharmaceuticals Inc.